Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2007-08-07
2007-08-07
Bunner, Bridget (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S350000, C530S351000, C530S402000, C424S085100, C514S012200
Reexamination Certificate
active
10773939
ABSTRACT:
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208158 (1993-05-01), Bech et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 6171824 (2001-01-01), Todaro et al.
patent: 2003/0166865 (2003-09-01), Cox
patent: 2003/0171284 (2003-09-01), Cox
patent: 0 458 064 (1991-11-01), None
patent: WO 93/00109 (1993-07-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/22466 (1994-10-01), None
patent: WO 95/11987 (1995-04-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 96/31537 (1996-10-01), None
Harmegnies et al., Characterization of a potent human interleukin-11 agonist, 2003, Biochemical Journal, vol. 375, pp, 23-32.
Campbell et al.,J. Peptide Res., 49:527-537 (1997)
Cunningham et al.,Science, 243:1330-1336 (1989).
Goodson and Katre,Bio/Technology, 8:343-346 (1990).
Karpusas et al.,Proc. Natl. Acad. Sci. USA, 94:11813-11818 (1997).
Lowman and Wells,J. Mol. Biol., 234:564-578 (1993).
Mott and Compbell,Curr Opin Struct Biol, 5:114-121 (1995).
Sprang and Bazan,Curr. Op. Struct. Biol., 3:815-827 (1993).
Wells,Ann. Rev. Biochem., 65:609-634 (1996).
Zalipsky, S.,Adv. Drug Delivery Rev., 16:157-182 (1995).
Paul et al., Proceedings of the National Academy of Sciences, USA, vol. 87, No. 19, pp. 7512-7516 (Oct. 1990).
Kawashima et al. FEBS Letters, vol. 283 No. 2, pp. 199-202 (Jun. 1991).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Barton et al., The Journal of Biological Chemistry, Vo. 274 No. 9, pp. 5755-5761 (Feb. 1999).
Tacken et al., European Journal of Biological Chemistry, Vo. 265 No. 2, pp. 645-655 (Oct. 1999).
Czupryn et al., Journal of Biological Chemistry, vol. 270 No. 2, pp. 978-985 (Jan. 1995).
Czupryn et al., Annals of the New York Academy of Sciences, vol. 762, pp. 152-164 (Jul. 1995).
Miyadi et al., Bioscience, Biotechnology and Biochemistry, vol. 60 No. 3, pp. 541-542 (Mar. 1996).
Wells, Biochemsitry, vol. 29 No. 37, pp. 8509-8517 (Sep. 1990).
Zhang et al., Pharmaceutical Research, vol. 19 No. 8, pp. 1223-1231 (Aug. 2002).
Yamasaki et al., Drugs Under Experimental and Clinical Research, vol. 24 No. 4, pp. 191-196 (1998).
Bolder Biotechnology Inc.
Bunner Bridget
Dang Ian
Sheridan & Ross P.C.
LandOfFree
Cysteine variants of interleukin-11 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine variants of interleukin-11, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine variants of interleukin-11 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840879